Dysregulated expression of histone deacetylases in medulloblastoma – potential targets for selective inhibitor treatment

Introduction: Medulloblastoma is the most common malignant brain tumor in childhood comprising 4 molecular subgroups. Survival rates remain particularly poor for patients with subgroup 3 tumors despite multimodal treatment. Therefore targeted therapies are urgently needed. Broad-spectrum inhibition of histone deacetylases (HDACs) has previously been shown to be a promising approach in cancer therapy. We here explore the possibility of isoenzyme-selective HDAC isozyme inhibition for treatment of MB. Methods: Gene expression profiles and tissue microarrays of medulloblastomas were analyzed for differential express…